<DOC>
	<DOCNO>NCT00811642</DOCNO>
	<brief_summary>The purpose multicenter , open label study , evaluate safety efficacy 12-week treatment Posaconazole Oral Suspension participant IFI</brief_summary>
	<brief_title>Posaconazole Treatment Invasive Fungal Infection ( IFI ) ( P05551 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Participants must 1870 year male female Identified clinically diagnose IFI participant high risk population resistant , recurrent , intolerable , may suffer toxic reaction standard antifungal treatment . Sign inform consent form Female participant pregnant nursing . Participants know suspected hypersensitivity idiosyncratic reaction azole agent amphotericin B Participants progressive nervous system disease ( exclude IFI cause ) Participants take follow drug know interference azole antifungal preparation terfenadine , cisapride , ebastine within 24 hour entry astemizole entry within 10 day entry cimetidine , rifampin , carbamazepine , phenytoin , rifabutin , barbiturate , isoniazid atharanthine anthracyclines within 24 hour entry The drug list prohibited investigation Serious organ diseases except hematological disorder cardiac neurologic disorder impairment expect unstable progressive course study ( eg , seizures demyelinate syndrome , acute myocardial infarction within 3 month study entry , myocardial ischemia , congestive heart failure , atrial fibrillation ventricular rate &lt; 60/min , history torsades de pointes , symptomatic ventricular sustain arrhythmia ) , unstable electrolyte abnormality . Participants ECG prolong QTc interval : QTc great 450 msec men great 470 msec woman . Expected take investigation take systemic antifungal treatment Participants severe renal insufficiency ( estimate creatinine clearance le 50 mL/minute likely require dialysis study ) , ALT , AST AKP total bilirubin &gt; 2Ã—ULN . Participants expect survive 72hrs Participants receive artificial aeration withdraw within 24hrs Participants use investigational drug biologic agent anticipated clinical trial within 30 day study entry . Prior enrollment study . History alcohol and/or drug abuse . Participants compliant investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>refractory first line medication intolerable invasive fungal infection</keyword>
</DOC>